DTIL SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 5, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWPrecision BioSciences Announces Pricing of Common Stock and Pre-Funded Warrant Offering

Nov 9, 2026

8-K

Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Nov 6, 2026

8-K

Precision BioSciences Announces Positive Phase 1 PBGENE-HBV Data and Advancement to Phase 2 for Chronic Hepatitis B

Nov 5, 2026

8-K

Precision BioSciences Reports Third Quarter 2026 Financial Results and Business Updates

Nov 3, 2026

8-K

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study for PBGENE-DMD

Aug 24, 2026

8-K

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 6, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Nov 5, 2026

424B5

REGISTERED OFFERING

Nov 12, 2025

424B5

March 2025 ATM

Mar 26, 2025

424B5

Mar 1, 2024

424B5

Distribution with Respect to Our Common Stock

Feb 29, 2024

424B4

OFFERING | Shares amount: 35,971,224 | Share price: $1.39 | Offering amount: $50,000,001.00

Jun 22, 2022

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 8, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 8, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 27, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 15, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 15, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 4, 2025

Ownerships

TYPE

HEADLINE

FILED AT

144

Form 144 - Report of proposed sale of securities

Nov 6, 2026

144

Form 144 - Report of proposed sale of securities

Nov 5, 2026

SCHEDULE 13G/A

Octagon Capital Advisors LP (Filed by)

Nov 3, 2026

SCHEDULE 13G

BlackRock, Inc. (Filed by)

Oct 27, 2026

Frankel Stanley (Reporting)

Sep 30, 2026

Brown Melinda (Reporting)

Sep 29, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 8, 2026

CORRESP

Form CORRESP - Correspondence

Jan 5, 2026

LETTER

Form UPLOAD - SEC-generated letter

Jan 2, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 16, 2023

CORRESP

Form CORRESP - Correspondence

Jun 13, 2023

LETTER

Form UPLOAD - SEC-generated letter

Jun 12, 2023

Precision BioSciences, Inc. DTIL · SEC Filings